• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Invivyd Reports First Quarter 2024 Financial Results and Recent Business Highlights

    5/9/24 4:01:00 PM ET
    $IVVD
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $IVVD alert in real time by email
    • Launched PEMGARDA™ in the U.S. for COVID-19 pre-exposure prophylaxis (PrEP) in certain adults and adolescents with moderate-to-severe immune compromise
    • Reported interim exploratory COVID-19 clinical event data from CANOPY Phase 3 clinical trial of VYD222
    • Received product-specific reimbursement codes covering PEMGARDA from the U.S. Centers for Medicare & Medicaid Services (CMS), covering approximately half of target population
    • Announced plans to pursue rapid immunobridging pathway to potential EUA for COVID-19 treatment in certain immunocompromised people, based on U.S. FDA feedback
    • Continued to advance VYD2311, the company's next monoclonal antibody candidate engineered with the company's state-of-the-art technologies for variant monitoring, predictive modeling and antibody engineering
    • Ended Q1 2024 with cash and cash equivalents of $189.4 million
    • Company expects to end 2024 with at least $75 million in cash and cash equivalents, based on anticipated 2024 net product revenue of $150-$200 million and recent resource realignment
    • Management to host conference call today at 4:30pm ET

    WALTHAM, Mass., May 09, 2024 (GLOBE NEWSWIRE) -- Invivyd, Inc. (NASDAQ:IVVD), a biopharmaceutical company devoted to delivering protection from serious viral infectious diseases, today announced financial results for the quarter ended March 31, 2024, and recent business highlights.

    "The recent months have been incredibly productive for Invivyd. Moving into the commercial phase is a critical step for the company and we are executing on the PEMGARDA launch with maximum focus across the company," said Marc Elia, Chairman of the Invivyd Board of Directors. "In addition, we look forward to sharing on today's quarterly update call more of the scientific underpinnings of our plans going forward, including detail on the innovative engine we believe can deliver meaningful product-level advancements with associated medical and economic value creation."

    Recent Business Highlights

    • Launched PEMGARDA, the company's first monoclonal antibody (mAb) in a planned series of innovative antibodies, in the U.S.: On March 22, 2024, PEMGARDA (pemivibart) received emergency use authorization (EUA) from the U.S. Food and Drug Administration (FDA) for the pre-exposure prophylaxis (PrEP) of COVID-19 in certain adults and adolescents with moderate-to-severe immune compromise. At the beginning of April, Invivyd announced that PEMGARDA is available for purchase in the U.S. through a network of authorized specialty distributors. At the end of April, Invivyd's market access and sales, as well as medical affairs, teams were fully operational across the U.S. The company will begin reporting PEMGARDA net product revenue with its second quarter 2024 financial results.
    • Received product-specific reimbursement codes covering PEMGARDA from the U.S. Centers for Medicare & Medicaid (CMS): In April 2024, Invivyd announced that CMS has granted a Healthcare Common Procedure Coding System (HCPCS) Q code (Q0224) covering product reimbursement and a product specific M code (M0224) covering the administration of PEMGARDA. The company estimates that CMS provides coverage for nearly half of the moderately to severely immunocompromised people at highest risk for severe COVID-19 that the company is initially targeting.
    • Reported interim exploratory COVID-19 clinical event data from CANOPY Phase 3 clinical trial of VYD222: In March 2024, Invivyd announced interim exploratory data from the ongoing CANOPY Phase 3 clinical trial that reflect and add further to the initial potential signal of clinical protection from symptomatic COVID-19 shared in December 2023. While not part of the primary immunobridging endpoint of the CANOPY clinical trial, the interim exploratory data may be hypothesis generating for future discovery and development work.

    Recent Pipeline Highlights

    • Announced plans to pursue rapid immunobridging pathway to potential EUA for COVID-19 treatment in certain immunocompromised people, based on U.S. FDA feedback: In May 2024, Invivyd announced that it anticipates imminently submitting an EUA application to the FDA for pemivibart for the treatment of mild to moderate symptomatic COVID-19 in certain immunocompromised people utilizing a rapid immunobridging pathway. This immunobridging pathway leverages a similar approach Invivyd used to achieve its current EUA for PEMGARDA for COVID-19 PrEP in certain immunocompromised people and was aligned in principle with the FDA.
    • Continued to advance VYD2311, the company's next anticipated mAb candidate: In March 2024, Invivyd announced that it expects that VYD2311 will be the next anti-SARS-CoV-2 mAb candidate that it advances into clinical development. VYD2311 is optimized for neutralization potency against recent SARS-CoV-2 lineages such as BA.2.86 and JN.1. The design of VYD2311 leverages Invivyd's state-of-the-art technologies for variant surveillance, predictive modeling, and antibody engineering.

    First Quarter 2024 Financial Results:

    • Cash Position: Cash and cash equivalents were $189.4 million as of March 31, 2024.
    • Projected 2024 Year-End Cash Position: Based on current operating plans, Invivyd expects to end 2024 with at least $75 million in cash and cash equivalents, based on anticipated 2024 net product revenue of $150 million to $200 million and recent resource realignment. Invivyd is maintaining its existing guidance, although the previously issued guidance was based on PEMGARDA being authorized for PrEP of COVID-19 in certain immunocompromised people and did not contemplate any potential sales for COVID-19 treatment, if authorized, or inventory build that may be required to deliver medicine timely to patients in need.
    • Research & Development (R&D) Expenses (including In-Process R&D): R&D expenses were $31.2 million for the quarter ended March 31, 2024, compared to $28.0 million for the comparable period of 2023. This increase is primarily attributable to an increase in commercial manufacturing costs of PEMGARDA and an increase in clinical trial costs related to the ongoing monitoring of our CANOPY Phase 3 clinical trial.
    • Selling, General & Administrative (SG&A) Expenses: SG&A expenses were $14.9 million for the quarter ended March 31, 2024, compared to $11.0 million for the comparable period of 2023. This increase is primarily attributable to an increase in personnel-related costs and commercial costs driven by the preparation for launch of PEMGARDA.
    • Net Loss and Net Loss per Share: Net loss was $43.5 million for the quarter ended March 31, 2024, compared to $35.3 million for the comparable period in 2023. Basic and diluted net loss per share was $0.38 for the quarter ended March 31, 2024, compared to $0.32 for the comparable period in 2023.

    Conference Call & Webcast

    Listeners can register for the webcast via this link. Analysts wishing to participate in the question and answer session should use this link. A replay of the webcast will be available via the company's investor website approximately two hours after the call's conclusion. Those who plan on participating are advised to join 15 minutes prior to the start time.

    About PEMGARDA

    PEMGARDA™ (pemivibart) is a half-life extended investigational monoclonal antibody (mAb). PEMGARDA was engineered from adintrevimab, Invivyd's investigational mAb that has a robust safety data package and provided evidence of clinical efficacy in a global Phase 2/3 clinical trial for the prevention and treatment of COVID-19. PEMGARDA has demonstrated in vitro neutralizing activity in pseudotyped virus-like particle and authentic virus neutralization assays against major SARS-CoV-2 variants, including JN.1. PEMGARDA targets the SARS-CoV-2 spike protein receptor binding domain (RBD), thereby inhibiting virus attachment to the human ACE2 receptor on host cells.

    PEMGARDA (pemivibart) injection (4500 mg), for intravenous use is an investigational mAb that has not been approved, but has been authorized for emergency use by the U.S. FDA under an EUA for the pre-exposure prophylaxis (prevention) of COVID-19 in adults and adolescents (12 years of age and older weighing at least 40 kg) who have moderate-to-severe immune compromise due to certain medical conditions or receipt of certain immunosuppressive medications or treatments and are unlikely to mount an adequate immune response to COVID-19 vaccination. Recipients should not be currently infected with or have had a known recent exposure to an individual infected with SARS-CoV-2. PEMGARDA is not authorized for use for treatment of COVID-19 or post-exposure prophylaxis of COVID-19. Anaphylaxis has been observed with PEMGARDA and the PEMGARDA Fact Sheet for Healthcare Providers includes a boxed warning for anaphylaxis. The most common adverse events (all grades, incidence ≥2%) observed in participants who have moderate-to-severe immune compromise treated with PEMGARDA included systemic and local infusion-related or hypersensitivity reactions, upper respiratory tract infection, viral infection, influenza-like illness, fatigue, headache, and nausea. For additional information, please see the PEMGARDA full product Fact Sheet for Healthcare Providers, including important safety information and boxed warning.

    To support the EUA for PEMGARDA, an immunobridging approach was used to determine if PEMGARDA may be effective for pre-exposure prophylaxis of COVID-19. Immunobridging is based on the serum virus neutralizing titer-efficacy relationships identified with other neutralizing human mAbs against SARS-CoV-2. This includes adintrevimab, the parent mAb of pemivibart, and other mAbs that were previously authorized for EUA. There are limitations of the data supporting the benefits of PEMGARDA. Evidence of clinical efficacy for other neutralizing human mAbs against SARS-CoV-2 was based on different populations and SARS-CoV-2 variants that are no longer circulating. Additionally, the variability associated with cell-based EC50 value determinations, along with limitations related to pharmacokinetic data and efficacy estimates for the mAbs in prior clinical trials, impact the ability to precisely estimate protective titer ranges.

    The emergency use of PEMGARDA is only authorized for the duration of the declaration that circumstances exist justifying the authorization of the emergency use of drugs and biological products during the COVID-19 pandemic under Section 564(b)(1) of the Federal Food, Drug, and Cosmetic Act, 21 U.S.C. § 360bbb-3(b)(1), unless the declaration is terminated or authorization revoked sooner.

    About Invivyd

    Invivyd, Inc. (NASDAQ:IVVD) is a biopharmaceutical company devoted to delivering protection from serious viral infectious diseases, beginning with SARS-CoV-2. The company's proprietary INVYMAB™ platform approach combines state-of-the-art viral surveillance and predictive modeling with advanced antibody engineering. INVYMAB is designed to facilitate the rapid, serial generation of new monoclonal antibodies (mAbs) to address evolving viral threats. In March 2024, Invivyd received emergency use authorization (EUA) from the U.S. FDA for its first mAb in a planned series of innovative antibody candidates. Visit https://invivyd.com/ to learn more.

    Cautionary Note Regarding Forward Looking Statements

    This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as "anticipates," "believes," "could," "expects," "intends," "potential," "projects," and "future" or similar expressions (as well as other words or expressions referencing future events, conditions or circumstances) are intended to identify forward-looking statements. Forward-looking statements include statements concerning, among other things, PEMGARDA as a mAb for COVID-19 PrEP in certain adults and adolescents with moderate-to-severe immune compromise; the company's plans and expectations related to the commercialization of PEMGARDA; the company's intention to pursue a rapid immunobridging pathway to potential EUA for COVID-19 treatment in certain immunocompromised people; the company's anticipated submission of a COVID-19 treatment EUA request to the FDA for pemivibart, and the timing thereof; the company's research and clinical development efforts, and the timing thereof; the potential of VYD222 for clinical protection from symptomatic COVID-19 based on interim exploratory data from the CANOPY Phase 3 clinical trial; the company's expectation that PEMGARDA is the first mAb in a planned series of innovative antibody candidates and VYD2311 will be the next mAb candidate to advance into clinical development; the future of the COVID-19 landscape; the company's belief that its innovative engine can deliver meaningful product-level advancements with associated medical and economic value creation; the company's anticipated 2024 net product revenue and projected 2024 year-end cash position; the company's commitment to delivering protection from serious viral infectious diseases, beginning with SARS-CoV-2; the design of the company's INVYMAB platform approach to facilitate the rapid, serial generation of new mAbs to address evolving viral threats; and other statements that are not historical fact. The company may not actually achieve the plans, intentions or expectations disclosed in the company's forward-looking statements and you should not place undue reliance on the company's forward-looking statements. These forward-looking statements involve risks and uncertainties that could cause the company's actual results to differ materially from the results described in or implied by the forward-looking statements, including, without limitation: how long the EUA granted by the FDA for PEMGARDA for COVID-19 PrEP in certain adults and adolescents with moderate-to-severe immune compromise will remain in effect and whether such EUA is revoked or revised by the FDA; the company's ability to maintain and expand sales, marketing and distribution capabilities to successfully commercialize PEMGARDA; changes in expected or existing competition; the company's ability to effectively utilize an immunobridging pathway to potential EUA for pemivibart for COVID-19 treatment in certain immunocompromised people; whether the company is able to successfully submit a COVID-19 treatment EUA request to the FDA, and the timing, scope and outcome of any such EUA request; uncertainties related to the regulatory authorization or approval process; changes in the regulatory environment; the timing and progress of the company's discovery, preclinical and clinical development activities; unexpected safety or efficacy data observed during preclinical studies or clinical trials; the ability to maintain a continued acceptable safety, tolerability and efficacy profile of PEMGARDA or any other product candidate following regulatory authorization or approval; the predictability of clinical success of the company's product candidates based on neutralizing activity in preclinical studies; the risk that results of preclinical studies or clinical trials may not be predictive of future results, and interim data are subject to further analysis; the company's reliance on third parties with respect to virus assay creation and product candidate testing and with respect to its clinical trials; variability of results in models used to predict activity against SARS-CoV-2 variants; whether PEMGARDA or any other product candidate is able to demonstrate and sustain neutralizing activity against major SARS-CoV-2 variants, particularly in the face of viral evolution; the complexities of manufacturing mAb therapies; the company's dependence on third parties to manufacture, label, package, store and distribute clinical and commercial supplies of its product candidates; whether the company is able to provide sufficient commercial supply of PEMGARDA to meet market demand; whether the company can obtain and maintain third-party coverage and adequate reimbursement for PEMGARDA or any other product candidate; the company's ability to deliver meaningful product-level advancements with associated medical and economic value creation; the company's ability to leverage its INVYMAB platform approach to facilitate the rapid, serial generation of new mAbs to address evolving viral threats; any litigation and other proceedings or government investigations relating to the company; the company's ability to continue as a going concern; the company's ability to optimize operating expenses; and whether the company has adequate funding to meet future operating expenses and capital expenditure requirements. Other factors that may cause the company's actual results to differ materially from those expressed or implied in the forward-looking statements in this press release are described under the heading "Risk Factors" in the company's Annual Report on Form 10-K for the year ended December 31, 2023 filed with the Securities and Exchange Commission (SEC), and in the company's other filings with the SEC, and in its future reports to be filed with the SEC and available at www.sec.gov. Forward-looking statements contained in this press release are made as of this date, and Invivyd undertakes no duty to update such information whether as a result of new information, future events or otherwise, except as required under applicable law.

    This press release contains hyperlinks to information that is not deemed to be incorporated by reference in this press release.

    Contacts:

    Media Relations

    (781) 208-0160

    [email protected]

    Investor Relations

    (781) 208-0160

    [email protected]



     
    INVIVYD, INC.

    CONDENSED CONSOLIDATED BALANCE SHEETS

    (UNAUDITED)

    (In thousands, except share and per share amounts)
     
      

     March 31,

    2024
     

    December 31,

    2023
     
    Assets     
    Current assets:     
    Cash and cash equivalents $189,388 $200,641 
    Inventory  109  — 
    Prepaid expenses and other current assets  20,386  24,240 
    Total current assets  209,883  224,881 
    Property and equipment, net  1,901  1,896 
    Operating lease right-of-use assets  1,827  2,229 
    Other non-current assets  1,857  175 
    Total assets $215,468 $229,181 
    Liabilities, Preferred Stock and Stockholders' Equity     
    Current liabilities:     
    Accounts payable $1,168 $7,953 
    Accrued expenses  34,003  40,860 
    Operating lease liabilities, current  1,134  1,443 
    Other current liability  40  35 
    Total current liabilities  36,345  50,291 
    Operating lease liabilities, non-current  625  722 
    Other non-current liability  —  700 
    Total liabilities  36,970  51,713 
    Commitments and contingencies     
    Stockholders' equity (deficit):     
    Preferred stock (undesignated), $0.0001 par value; 10,000,000 shares

    authorized and no shares issued and outstanding at March 31, 2024

    and December 31, 2023
      —  — 
    Common stock, $0.0001 par value; 1,000,000,000 shares authorized,

    119,221,230 shares issued and outstanding at March 31, 2024;

    110,160,684 shares issued and outstanding at December 31, 2023
      12  11 
    Additional paid-in capital  954,063  909,539 
    Accumulated other comprehensive loss  (12) (13)
    Accumulated deficit  (775,565) (732,069)
    Total stockholders' equity  178,498  177,468 
    Total liabilities, preferred stock and stockholders' equity $215,468 $229,181 



     
    INVIVYD, INC.

    CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS

    (UNAUDITED)

    (In thousands, except share and per share amounts)
     
      Three Months

    Ended

    March 31,
      Three Months

    Ended

    March 31,
     
      2024  2023 
    Operating expenses:      
    Research and development(1) $31,160  $27,201 
    Acquired in-process research and development(2)  —   825 
    Selling, general and administrative  14,929   11,045 
    Total operating expenses  46,089   39,071 
    Loss from operations  (46,089)  (39,071)
    Other income:      
    Other income, net  2,593   3,750 
    Total other income, net  2,593   3,750 
    Net loss  (43,496)  (35,321)
    Other comprehensive income (loss)      
    Unrealized gain on available-for-sale securities, net of tax  1   157 
    Comprehensive loss $(43,495) $(35,164)
    Net loss per share attributable to common stockholders, basic and diluted $(0.38) $(0.32)
    Weighted-average common shares outstanding, basic and diluted  115,618,209   108,785,519 



    (1)    Includes related-party amounts of $1,135 and $2,960 for the three months ended March 31, 2024 and 2023, respectively.

    (2)    Includes related-party amounts of $0 and $375 for the three months ended March 31, 2024 and 2023, respectively.



    Primary Logo

    Get the next $IVVD alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $IVVD

    DatePrice TargetRatingAnalyst
    4/5/2024$9.00Neutral → Buy
    Guggenheim
    3/26/2024$4.00 → $10.00Equal-Weight → Overweight
    Morgan Stanley
    12/19/2023$1.00 → $4.00Underweight → Equal-Weight
    Morgan Stanley
    5/1/2023$5.00Buy
    H.C. Wainwright
    More analyst ratings

    $IVVD
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Invivyd Appoints Paul B. Bolno, M.D. to Its Board of Directors

    NEW HAVEN, Conn., Sept. 24, 2025 (GLOBE NEWSWIRE) -- Invivyd, Inc. (NASDAQ:IVVD) today announced the appointment of Paul B. Bolno, M.D., to its Board of Directors and as a member of the Compensation Committee. Dr. Bolno is the President and CEO of Wave Life Sciences, a clinical-stage biotechnology company, and has served in those roles since 2013. "We are happy to have Dr. Bolno join our Board at this critical moment while we transition toward a future focused on helping large populations avoid becoming ill from major viral infectious diseases," said Marc Elia, Chairman of the Board of Invivyd. "Dr. Bolno's extensive experience in leading Wave Life Sciences through rapid pipeline developm

    9/24/25 4:01:00 PM ET
    $IVVD
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Invivyd Announces Appointment of Kristie Kuhl as Chief Communications Officer

    NEW HAVEN, Conn., Sept. 17, 2025 (GLOBE NEWSWIRE) -- Invivyd, Inc. (NASDAQ:IVVD) today announced the appointment of Kristie Kuhl as Chief Communications Officer. Ms. Kuhl will lead the Company's communications and patient advocacy efforts as Invivyd advances its mission of providing monoclonal antibodies for the prevention and treatment of viral disease. Ms. Kuhl brings deep expertise in healthcare and pharmaceutical communications, and she has been recognized by industry media for her influence in health communications, including PRWeek's 2024 Health Influencer 30. She most recently served as Global Managing Director, Health & Wellness at Zeno Group, where she led the firm's healthcare p

    9/17/25 7:01:20 AM ET
    $IVVD
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SPEAR Study Group to Present its Recommended Long COVID Antibody Study Design Featuring Invivyd's VYD2311 At RECOVER-TLC Workshop September 9-10, 2025

    SPEAR proposal reflects current evidence on monoclonal antibodies in treatment for Long COVID and identifies VYD2311 as a promising next-generation candidate for the clinical study Recommendation is for a robust, comprehensive, translational study to evaluate the ability of VYD2311 to decrease circulating spike protein in eligible patients and to explore potential associated clinical benefits Study design contemplates maintaining high antiviral antibody titers over an extended period to maximally suppress underlying chronic infection that may drive Long COVID pathologyDrs. Amy Proal and David Putrino to present on behalf of SPEAR Study Group WALTHAM, Mass., Sept. 04, 2025 (GLOBE NEWSWIR

    9/4/25 7:01:00 AM ET
    $IVVD
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $IVVD
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Invivyd upgraded by Guggenheim with a new price target

    Guggenheim upgraded Invivyd from Neutral to Buy and set a new price target of $9.00

    4/5/24 7:50:41 AM ET
    $IVVD
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Invivyd upgraded by Morgan Stanley with a new price target

    Morgan Stanley upgraded Invivyd from Equal-Weight to Overweight and set a new price target of $10.00 from $4.00 previously

    3/26/24 8:01:17 AM ET
    $IVVD
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Invivyd upgraded by Morgan Stanley with a new price target

    Morgan Stanley upgraded Invivyd from Underweight to Equal-Weight and set a new price target of $4.00 from $1.00 previously

    12/19/23 7:28:14 AM ET
    $IVVD
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $IVVD
    SEC Filings

    View All

    $IVVD
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form S-3 filed by Invivyd Inc.

    S-3 - Invivyd, Inc. (0001832038) (Filer)

    10/2/25 4:11:11 PM ET
    $IVVD
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Invivyd Inc. filed SEC Form 8-K: Leadership Update, Regulation FD Disclosure, Other Events, Financial Statements and Exhibits

    8-K - Invivyd, Inc. (0001832038) (Filer)

    9/24/25 4:45:16 PM ET
    $IVVD
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form SCHEDULE 13G filed by Invivyd Inc.

    SCHEDULE 13G - Invivyd, Inc. (0001832038) (Subject)

    9/8/25 1:07:52 PM ET
    $IVVD
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 4 filed by Director Bolno Paul

    4 - Invivyd, Inc. (0001832038) (Issuer)

    9/24/25 5:07:54 PM ET
    $IVVD
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 3 filed by new insider Bolno Paul

    3 - Invivyd, Inc. (0001832038) (Issuer)

    9/24/25 5:04:38 PM ET
    $IVVD
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Chief Commercial Officer Lee Timothy Edward converted options into 99,000 shares and sold $29,808 worth of shares (49,656 units at $0.60), increasing direct ownership by 493% to 59,344 units (SEC Form 4)

    4 - Invivyd, Inc. (0001832038) (Issuer)

    8/19/25 9:28:22 PM ET
    $IVVD
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $IVVD
    Leadership Updates

    Live Leadership Updates

    View All

    Invivyd Appoints Paul B. Bolno, M.D. to Its Board of Directors

    NEW HAVEN, Conn., Sept. 24, 2025 (GLOBE NEWSWIRE) -- Invivyd, Inc. (NASDAQ:IVVD) today announced the appointment of Paul B. Bolno, M.D., to its Board of Directors and as a member of the Compensation Committee. Dr. Bolno is the President and CEO of Wave Life Sciences, a clinical-stage biotechnology company, and has served in those roles since 2013. "We are happy to have Dr. Bolno join our Board at this critical moment while we transition toward a future focused on helping large populations avoid becoming ill from major viral infectious diseases," said Marc Elia, Chairman of the Board of Invivyd. "Dr. Bolno's extensive experience in leading Wave Life Sciences through rapid pipeline developm

    9/24/25 4:01:00 PM ET
    $IVVD
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Invivyd Announces Appointment of Kristie Kuhl as Chief Communications Officer

    NEW HAVEN, Conn., Sept. 17, 2025 (GLOBE NEWSWIRE) -- Invivyd, Inc. (NASDAQ:IVVD) today announced the appointment of Kristie Kuhl as Chief Communications Officer. Ms. Kuhl will lead the Company's communications and patient advocacy efforts as Invivyd advances its mission of providing monoclonal antibodies for the prevention and treatment of viral disease. Ms. Kuhl brings deep expertise in healthcare and pharmaceutical communications, and she has been recognized by industry media for her influence in health communications, including PRWeek's 2024 Health Influencer 30. She most recently served as Global Managing Director, Health & Wellness at Zeno Group, where she led the firm's healthcare p

    9/17/25 7:01:20 AM ET
    $IVVD
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Invivyd Appoints Ajay Royan, Founder of Mithril Capital, to its Board of Directors

    WALTHAM, Mass., March 26, 2025 (GLOBE NEWSWIRE) -- Invivyd, Inc. (NASDAQ:IVVD) is pleased to announce the appointment of Ajay Royan to its Board of Directors. Mr. Royan is a venture capitalist focused on transformational companies that have solved critical problems in healthcare, technology, and energy. Mr. Royan's investment firm, Mithril, is a significant long-term holder of Invivyd stock, and Mr. Royan led the 2022 shareholder action that focused Invivyd on its mission to deliver protection from serious viral infectious diseases, starting with COVID-19. "We are delighted by Ajay's return to the Board of Invivyd as the company prepares to take the next step forward in scaling the medica

    3/26/25 4:15:46 PM ET
    $IVVD
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $IVVD
    Financials

    Live finance-specific insights

    View All

    Invivyd Reports First Quarter 2025 Financial Results and Recent Business Highlights

    PEMGARDA™ (pemivibart) net product revenue of $11.3 million reported for Q1 2025, influenced by planned transition (Jan/Feb) from a contracted to an internalized sales forcePEMGARDA revenue re-acceleration observed in Q2 2025 to dateInvivyd continues to target near-term profitability (1H 2025) with existing cash and cash equivalents, anticipated growth of net product revenue, and continued reduction of operating expensesSince Emergency Use Authorization (EUA) of PEMGARDA in March 2024, no documented cases of anaphylaxis reported, across thousands of post-authorization dosesVYD2311 Phase 1 clinical trial data read-out anticipated later in Q2 2025 WALTHAM, Mass., May 15, 2025 (GLOBE NEWSWIR

    5/15/25 7:01:00 AM ET
    $IVVD
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Invivyd to Host First Quarter 2025 Financial Results and Corporate Update Conference Call on May 15, 2025

    WALTHAM, Mass., May 08, 2025 (GLOBE NEWSWIRE) -- Invivyd, Inc. (NASDAQ:IVVD), a biopharmaceutical company devoted to delivering protection from serious viral infectious diseases, today announced that it will host a conference call on Thursday, May 15, 2025, at 8:30 a.m. ET to discuss its financial results for the first quarter ended March 31, 2025, and provide recent business highlights. Listeners can register for the webcast via this link. Analysts wishing to participate in the question-and-answer session should use this link and are advised to join 15 minutes prior to the start time. A replay of the webcast will be available via the company's investor relations website approximately two

    5/8/25 7:01:00 AM ET
    $IVVD
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Invivyd Reports Third Quarter 2024 Financial Results and Recent Business Highlights

    Q3 2024 PEMGARDA™ (pemivibart) net product revenue of $9.3 million; Invivyd ended Q3 2024 with $106.9 million in cash and cash equivalentsTargets near-term (1H 2025) profitability with existing cash and cash equivalents, anticipated growth of net product revenue, and various operational efficiency improvementsPEMGARDA Fact Sheet updated to properly reflect neutralization activity of PEMGARDA against current circulating variants tested; on track for continued growth now reflective of ongoing commercial optimizationNext generation molecule VYD2311 first-in-human clinical trial dosing began in August 2024 with anticipated preliminary data readout late Q4 2024Management to host conference call t

    11/14/24 7:05:00 AM ET
    $IVVD
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $IVVD
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by Invivyd Inc.

    SC 13D/A - Invivyd, Inc. (0001832038) (Subject)

    12/12/24 4:39:09 PM ET
    $IVVD
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SC 13G/A filed by Invivyd Inc.

    SC 13G/A - Invivyd, Inc. (0001832038) (Subject)

    11/14/24 4:30:58 PM ET
    $IVVD
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SC 13G/A filed by Invivyd Inc.

    SC 13G/A - Invivyd, Inc. (0001832038) (Subject)

    11/14/24 9:16:35 AM ET
    $IVVD
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care